Mitch Dowsett

发表

Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer

Jack Cuzick, Ivana Sestak, Mitch Dowsett, 2013, Journal of the National Cancer Institute.

Abstract P1-01-01: Analytical validation of a standardized scoring protocol for Ki67: Phase-3 of an international multicenter collaboration

John M S Bartlett, Indu Arun, Mitch Dowsett, 2016 .

Current and emerging biomarkers in breast cancer: prognosis and prediction.

Mitch Dowsett, M. Dowsett, M. Weigel, 2010, Endocrine-related cancer.

Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation

Alan Mackay, Chris Jones, Alan Ashworth, 2007, Laboratory Investigation.

High‐throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium

Peter Devilee, Arto Mannermaa, Annegien Broeks, 2016, The journal of pathology. Clinical research.

Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.

Mitch Dowsett, Roger A'Hern, M. Dowsett, 2007, Journal of the National Cancer Institute.

Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance

Alan Ashworth, Mitch Dowsett, A. Ashworth, 2006, Breast Cancer Research and Treatment.

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

David Cameron, Richard Bell, Mitch Dowsett, 2017, The Lancet.

Aromatase inhibitors for breast cancer: lessons from the laboratory

Mitch Dowsett, M. Dowsett, S. Johnston, 2003, Nature Reviews Cancer.

Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor–positive breast cancers

Mitch Dowsett, M. Dowsett, Z. Ghazoui, 2014, Breast Cancer Research.

Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration

Tomoharu Sugie, Indu Arun, Mitch Dowsett, 2019, Histopathology.

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

Anthony Rhodes, Paul Valenstein, Keith Miller, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer

Jack Cuzick, Richard Buus, Ivana Sestak, 2018, Breast Cancer Research.

Microenvironmental Heterogeneity Parallels Breast Cancer Progression: A Histology–Genomic Integration Analysis

Chris Bakal, Mitch Dowsett, Heba Sailem, 2016, PLoS medicine.

A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance

Yu Shyr, Gordon B Mills, Mitch Dowsett, 2011, Clinical Cancer Research.

Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.

Jack Cuzick, Valerie Speirs, Mitch Dowsett, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer

Mitch Dowsett, M. Dowsett, J. Richman, 2018, Nature Reviews Clinical Oncology.

Mechanisms of tamoxifen resistance.

Mitch Dowsett, M. Dowsett, A. Ring, 2004, Endocrine-related cancer.

Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study

Jack Cuzick, Mitch Dowsett, Lila Zabaglo, 2012, Breast Cancer Research.

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5

Jack Cuzick, Ivana Sestak, Mitch Dowsett, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer

Andreas Makris, Frances Daley, Mitch Dowsett, 2006, Breast Cancer Research.

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer

Jorge S. Reis-Filho, Rosalind J. Cutts, Mitch Dowsett, 2015, Science Translational Medicine.

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.

Jack Cuzick, Ivana Sestak, Mitch Dowsett, 2010, The Lancet. Oncology.

Microarray-Based Class Discovery for Molecular Classification of Breast Cancer: Analysis of Interobserver Agreement

Jorge S. Reis-Filho, Alan Mackay, Alan Ashworth, 2011, Journal of the National Cancer Institute.

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity

Mitch Dowsett, Frédérique Penault-Llorca, M. Dowsett, 2014, Modern Pathology.

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

David Cameron, Richard Bell, Mitch Dowsett, 2007, The Lancet.

Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance

Steffi Oesterreich, Simak Ali, Jason Carroll, 2017, Nature Communications.

An international Ki67 reproducibility study.

John M S Bartlett, Mitch Dowsett, Lisa M McShane, 2013, Journal of the National Cancer Institute.

Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.

Mitch Dowsett, Marion Procter, Brian Leyland-Jones, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mechanisms of Disease: angiogenesis and the management of breast cancer

Alan Ashworth, Mitch Dowsett, A. Ashworth, 2007, Nature Clinical Practice Oncology.

Cell filtration‐laser scanning cytometry for the characterisation of circulating breast cancer cells

Mitch Dowsett, Lila Zabaglo, M. Dowsett, 2003, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.

Jack Cuzick, Mitch Dowsett, Michael Baum, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines

Alan Mackay, Chris Jones, Alan Ashworth, 2008, Laboratory Investigation.

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

Mike Clarke, Yasuo Ohashi, Michael Gnant, 2018, The Lancet. Oncology.

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

John M S Bartlett, Patrick Fitzgibbons, Mitch Dowsett, 2014, Archives of pathology & laboratory medicine.

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Mitch Dowsett, Gerhardt Attard, Johann S de Bono, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.

Mitch Dowsett, Helen Anderson, Roger A'Hern, 2011, Journal of the National Cancer Institute. Monographs.

Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study

Patrick Neven, Chiun-Sheng Huang, Julian Peto, 2014, Breast Cancer Research.

Beyond Anatomic Staging: Are We Ready to Take the Leap to Molecular Classification?

Mitch Dowsett, Eric P. Winer, Lisa A. Carey, 2005 .

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

Anthony Rhodes, Paul Valenstein, Keith Miller, 2010, Archives of pathology & laboratory medicine.

Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer

Mitch Dowsett, M. Dowsett, A. Dunbier, 2008, Clinical Cancer Research.

20‐Year Risks of Breast‐Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

Daniel F. Hayes, Mitch Dowsett, Jonas Bergh, 2017, The New England journal of medicine.

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.

Jack Cuzick, Lisa McShane, Christos Sotiriou, 2011, Journal of the National Cancer Institute.

ESR 1 Is Co-Expressed with Closely Adjacent Uncharacterised Genes Spanning a Breast Cancer Susceptibility Locus at 6 q 25 . 1

Mitch Dowsett, Helen Anderson, M. Dowsett, 2012 .

Phytoestrogen concentrations in serum and spot urine as biomarkers for dietary phytoestrogen intake and their relation to breast cancer risk in European prospective investigation of cancer and nutrition-norfolk.

Mitch Dowsett, Kay-Tee Khaw, Angela A Mulligan, 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

John M S Bartlett, Patrick Fitzgibbons, Mitch Dowsett, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of type of full-field digital image on mammographic density assessment and breast cancer risk estimation: a case-control study

Mitch Dowsett, Rachel Denholm, Sarah Vinnicombe, 2016, Breast Cancer Research.

An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer

John M S Bartlett, Liron Pantanowitz, Carsten Denkert, 2018, Modern Pathology.

Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.

Jack Cuzick, Ivana Sestak, Mitch Dowsett, 2013, The Lancet. Oncology.

Aromatase inhibitors in breast cancer.

Mitch Dowsett, M. Dowsett, I. Smith, 2003, The New England journal of medicine.

ESR1 Is Co-Expressed with Closely Adjacent Uncharacterised Genes Spanning a Breast Cancer Susceptibility Locus at 6q25.1

Mitch Dowsett, Helen Anderson, M. Dowsett, 2011, PLoS genetics.

An international study to increase concordance in Ki67 scoring

John M S Bartlett, Mitch Dowsett, Lisa M McShane, 2015, Modern Pathology.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).

Anthony Rhodes, Paul Valenstein, Keith Miller, 2010, Archives of pathology & laboratory medicine.

Proliferation marker Ki-67 in early breast cancer.

Mitch Dowsett, M. Dowsett, A. Urruticoechea, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pre-clinical validation of early molecular markers of sensitivity to aromatase inhibitors in a mouse model of post-menopausal hormone-sensitive breast cancer

Mitch Dowsett, Xavier Solé, Gabriel Capellà, 2007, Breast Cancer Research and Treatment.

Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer-Clinical Notice

Anthony Rhodes, Paul Valenstein, Daniel F. Hayes, 2010 .

Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.

Jack Cuzick, Ivana Sestak, Mitch Dowsett, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics

Jingqin Luo, Mitch Dowsett, Matthew J. Ellis, 2008, Journal of the National Cancer Institute.

The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis

Alan Mackay, Alan Ashworth, Mitch Dowsett, 2006, Breast Cancer Research.